CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 60 enrolled
Drug / intervention
Methylphenidate +1 moredrug
Likely dose
Methylphenidate 5mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00495820
NCT00495820Phase 4Completed
CompareCT.gov

Methylphenidate for Apathy in Alzheimer's Dementia: A Controlled Study

VA Office of Research and Development·interventional·Posted Jul 3, 2007·Updated Nov 20, 2015

In Brief

A Phase 4 clinical trial evaluating Methylphenidate and Placebo for Alzheimer's Disease and 2 related conditions. Completed, enrolled 60 participants across 1 site.

Detailed Summary

The purpose of the study is to determine the efficacy of methylphenidate over placebo in treating apathy in patients with Alzheimer's dementia. Apathy is one of the earliest and most profound disturbances that occur in Alzheimer's dementia (AD). Hypotheses: 1. Methylphenidate (MPH) will improve apathy significantly more than placebo in AD. 2\. Successful treatment of apathy will improve Instrumental Activities of Daily Living (IADLs), and caregiver burden.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer's Disease, Apathy, Dementia
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 3, 2007
Enrollment StartAug 1, 2007
Primary CompletionMar 1, 2010
Study CompletionJun 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 19.0 years ago

Interventions

Methylphenidatedrug

Subject will receive 5mg twice a day for two weeks then 10mg twice a day until week 12 of the study.

Placeboother

Standard inactive pill.